Versant Ventures related stories
All articles and analysis
- Shaking The MoneyTree: VC Investment (Still) Rises in Q2
Stop me if you've heard this one before: Venture capital investing increased in the second-quarter of 2009, even though investment activity was still much lower than in Q2 2008. Oh yeah, we wrote about it over the weekend /45026/venture-capital-funding-rises-in-q2-healthcare-tops-it/ (and have been What's different this time is that the data comes from MoneyTree, a joint venture of the National Venture Capital Association, PwC and Thomson Reuters. That last one just happens to publish peHUB, which means we trust these numbers a bit more, have access to the actual database and are able to display a gluttonous smorgasborg of charts (see below). The topline number is $3.7 billion invested in 612 U.S.-based companies. This compares to $3.19 billion raised by 601 U.S.-based companies in Q1 2009, and $7.55 billion raised by 1,048 U.S.-based companies in Q2 2008. To use a semi-apt sports analogy, VCs took a baby step off the sidelines, but are nowhere near the line of scrimmage (particularly given that barely over $300 million has been invested thus far in Q3). In terms of industy sectors, IT managed to (barely) keep its unbeaten streak alive against life sciences ($1.72b vs. $1.53b). This is different than what the earlier data from Dow Jones showed, and MoneyTree does show biotech as its fattest cash cow in a more segmented analysis.
- Preliminary VC Deal Data Shows Mixed Bag
Venture capitalists invested $2.94 billion into 360 U.S.-based companies during the second quarter, according to preliminary, unaudited data from Thomson Reuters (publisher of peHUB). That’s down significantly from the $7.57 billion investors put into 1,042 companies during the same period in 2008, although is beginning to approach the $3.1 billion invested in Q1 2009 (and will probably top it, once all the surveys are counted). The official MoneyTree report from the National Venture Capital Association and PricewaterhouseCoopers, based on Thomson Reuters data, is expected to come out later this month. Biotechnology and health care investments buoyed the investment totals in Q2, accounting for nearly 45% of the dollars put to work during the three-month period. Four of the 10 largest deals done the quarter were health care deals. Investors put $145 million into anti-cancer company Clovis Oncology; $108 million into orthopedics company Small Bone Innovations; $50 million into light-therapy company PhotoThera; and $46 million into anti-infective medicine developer Cempra Pharmaceuticals.
- VC deal activity slowed in Q2
Fund-raising also dropped as only 14 firms successfully raised commitments for their funds
- Week in deals, June 29, 2009
Summary of tech companies and other businesses that raised financing in North America in the past week
- I-Therapeutix Raises $15 Million
I-Therapeutix, a Waltham, Mass.-based, has raised $15 million in Series C funding. Polaris Venture Partners led the round, and was joined by return backers Versant Ventures and SV Life Sciences.
- peHUB Wire: Tuesday, June 23, 2009
Random Ramblings
- peHUB Wire: Tuesday, June 23, 2009
Random Ramblings
- EyeIC gets OK for glaucoma-screening software
Startup has now raised $1.9M in a Series A round
- Cancer fighting startups raise cash
Aragon Pharmaceuticals, Clovis Oncology raised VC funding last week